{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T02:22:43Z","timestamp":1792462963533,"version":"4.5.0"},"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2017,4,18]],"date-time":"2017-04-18T00:00:00Z","timestamp":1492473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"UK NIHR Efficacy and Mechanism Evaluation Programme","award":["08\/43\/15"],"award-info":[{"award-number":["08\/43\/15"]}]},{"DOI":"10.13039\/501100012295","name":"Newcastle NIHR Biomedical Research Centre","doi-asserted-by":"crossref","award":["BH134439\/PD0117"],"award-info":[{"award-number":["BH134439\/PD0117"]}],"id":[{"id":"10.13039\/501100012295","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0175717","type":"journal-article","created":{"date-parts":[[2017,4,18]],"date-time":"2017-04-18T17:32:02Z","timestamp":1492536722000},"page":"e0175717","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":50,"title":["A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5638-2453","authenticated-orcid":true,"given":"Stuart","family":"McPherson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Tiniakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair D.","family":"Burt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"McColl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah D.","family":"Stocken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Steen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Goudie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Bury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin M.","family":"Anstee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,4,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"d3897","DOI":"10.1136\/bmj.d3897","article-title":"How big a problem is non-alcoholic fatty liver disease?","volume":"343","author":"QM Anstee","year":"2011","journal-title":"BMJ"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1136\/gutjnl-2011-300342","article-title":"Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography","volume":"61","author":"VW Wong","year":"2012","journal-title":"Gut"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/hep.20466","article-title":"Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity","volume":"40","author":"JD Browning","year":"2004","journal-title":"Hepatology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1002\/hep.25762","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association","volume":"55","author":"N Chalasani","year":"2012","journal-title":"Hepatology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1053\/j.gastro.2014.07.056","article-title":"Pathological Features of Fatty Liver Disease","volume":"147","author":"MM Yeh","year":"2014","journal-title":"Gastroenterology"},{"key":"ref6","article-title":"Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies","author":"S Singh","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1136\/gut.2009.205088","article-title":"Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years","volume":"59","author":"VW Wong","year":"2010","journal-title":"Gut"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.jhep.2014.11.034","article-title":"Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management","volume":"62","author":"S McPherson","year":"2015","journal-title":"J Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jhep.2013.04.027","article-title":"A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver","volume":"59","author":"R Pais","year":"2013","journal-title":"J Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/hep.21327","article-title":"Long-term follow-up of patients with NAFLD and elevated liver enzymes","volume":"44","author":"M Ekstedt","year":"2006","journal-title":"Hepatology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1002\/hep.24268","article-title":"Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality","volume":"53","author":"ZM Younossi","year":"2011","journal-title":"Hepatology"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"M Ekstedt","year":"2015","journal-title":"Hepatology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease","volume":"149","author":"P Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1136\/flgastro-2013-100404","article-title":"Non-alcoholic fatty liver disease: a practical approach to treatment","volume":"5","author":"JK Dyson","year":"2014","journal-title":"Frontline Gastroenterol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis","volume":"149","author":"E Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jhep.2011.06.010","article-title":"Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review","volume":"56","author":"C Thoma","year":"2012","journal-title":"J Hepatol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1136\/gutjnl-2014-306842","article-title":"Pathobiology of liver fibrosis: a translational success story","volume":"64","author":"YA Lee","year":"2015","journal-title":"Gut"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0016-5085(03)00695-4","article-title":"Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II","volume":"125","author":"R Bataller","year":"2003","journal-title":"Gastroenterology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1002\/hep.20665","article-title":"Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats","volume":"41","author":"R Bataller","year":"2005","journal-title":"Hepatology"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.peptides.2014.10.005","article-title":"The role of renin-angiotensin system modulation on treatment and prevention of liver diseases","volume":"62","author":"S Moreira de Macedo","year":"2014","journal-title":"Peptides"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1053\/gast.2001.25480","article-title":"Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis","volume":"121","author":"JR Jonsson","year":"2001","journal-title":"Gastroenterology"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/hep.23419","article-title":"Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats","volume":"51","author":"M Moreno","year":"2010","journal-title":"Hepatology"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1002\/hep.21638","article-title":"Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis","volume":"45","author":"A Hirose","year":"2007","journal-title":"Hepatology"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1002\/hep.20420","article-title":"Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis","volume":"40","author":"S Yokohama","year":"2004","journal-title":"Hepatology"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"942","DOI":"10.3748\/wjg.15.942","article-title":"Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis","volume":"15","author":"EF Georgescu","year":"2009","journal-title":"World J Gastroenterol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1002\/hep.24558","article-title":"Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial","volume":"54","author":"DM Torres","year":"2011","journal-title":"Hepatology"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"DE Kleiner","year":"2005","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"ref28","first-page":"S5","article-title":"Diagnosis and classification of diabetes mellitus","volume":"27","year":"2004","journal-title":"Diabetes Care"},{"key":"ref29","article-title":"CG43 Obesity: the prevention, identification, assessment and management of overweight and obesity in adults and children","year":"2006"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/hep.21984","article-title":"Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers","volume":"47","author":"IN Guha","year":"2008","journal-title":"Hepatology"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1136\/gut.2010.216077","article-title":"Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease","volume":"59","author":"S McPherson","year":"2010","journal-title":"Gut"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/hep.20092","article-title":"Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial","volume":"39","author":"KD Lindor","year":"2004","journal-title":"Hepatology"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1053\/j.gastro.2008.06.047","article-title":"Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis","volume":"135","author":"GP Aithal","year":"2008","journal-title":"Gastroenterology"},{"issue":"4, S1","key":"ref34","first-page":"716A","article-title":"Losartan reduces the expression of profibrogenic genes and inflammation in patients with chronic hepatitis C","volume":"46","author":"J Colmenero","year":"2007","journal-title":"Hepatology"},{"key":"ref35","article-title":"Hypertension in adults: diagnosis and management","year":"2011"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1053\/j.gastro.2014.11.039","article-title":"Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States","volume":"148","author":"RJ Wong","year":"2015","journal-title":"Gastroenterology"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/liv.12611","article-title":"Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease","volume":"35","author":"GB Goh","year":"2015","journal-title":"Liver Int"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/hep.22745","article-title":"Computer-assisted image analysis of liver collagen: relationship to Ishak scoring and hepatic venous pressure gradient","volume":"49","author":"V Calvaruso","year":"2009","journal-title":"Hepatology"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/S0168-8278(96)80285-6","article-title":"Permanent response to alpha-interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum","volume":"25","author":"S Ampurdanes","year":"1996","journal-title":"J Hepatol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"327","DOI":"10.4254\/wjh.v4.i12.327","article-title":"Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment","volume":"4","author":"P Paschos","year":"2012","journal-title":"World journal of hepatology"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1053\/gast.2002.36561","article-title":"Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver","volume":"123","author":"G Paizis","year":"2002","journal-title":"Gastroenterology"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jhep.2007.12.019","article-title":"NF-kappaB is a critical regulator of the survival of rodent and human hepatic myofibroblasts","volume":"48","author":"MR Watson","year":"2008","journal-title":"J Hepatol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s11892-007-0007-5","article-title":"The renin-angiotensin system and insulin resistance","volume":"7","author":"Z Liu","year":"2007","journal-title":"Curr Diab Rep"},{"key":"ref44","first-page":"448","article-title":"Do angiotensin converting enzyme inhibitors or angiotensin receptor blockers prevent diabetes mellitus? A meta-analysis","volume":"17","author":"M Al-Mallah","year":"2010","journal-title":"Cardiology journal"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0175717","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T22:54:34Z","timestamp":1750200874000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0175717"}},"subtitle":[],"editor":[{"given":"Vincent","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,4,18]]},"references-count":44,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,4,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0175717","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,18]]}}}